1. Androstenediol-induced restoration of responsiveness to influenza vaccination in mice.
- Author
-
Padgett DA, MacCallum RC, Loria RM, and Sheridan JF
- Subjects
- Age Factors, Animals, Chi-Square Distribution, Germ-Free Life, Immunity, Active drug effects, Immunity, Active immunology, Immunization, Secondary, Immunoglobulin G blood, Influenza A virus immunology, Mice, Mice, Inbred C57BL, Mice, Inbred Strains, Time Factors, Treatment Outcome, Aging immunology, Anabolic Agents therapeutic use, Androstenediol therapeutic use, Immunocompetence drug effects, Influenza Vaccines administration & dosage, Vaccination
- Abstract
Androstenediol (AED), a metabolite of dehydroepiandrosterone (DHEA) regulates innate and adaptive immune responses. To examine whether AED could effectively reverse the age-associated decline of antiviral immunity, 3-, 10-, and 22-month-old mice were treated with AED-sulfate (AED-S) for 45 days beginning 10 days prior to vaccination. Subsequently, mice were primed and boosted with suboptimal doses of a commercially-available trivalent influenza vaccine. Treatment of 10-month-old animals with AED-S during vaccination increased the titer of circulating antiviral immunoglobulin G to levels comparable with those in 3-month-old mice. Furthermore, AED-S treatment protected 10-month-old animals from intranasal challenge with a lethal dose of influenza virus 21 days after secondary vaccination. Although AED-S treatment of 22-month-old mice did not enhance vaccine responses and failed to protect against lethal challenge, the data from the 10-month-old animals suggest that treatment with AED-S will prevent the early manifestations of immunosenescence.
- Published
- 2000
- Full Text
- View/download PDF